Navigation Links
Low dose of targeted drug might improve cancer-killing virus therapy
Date:6/16/2014

COLUMBUS, Ohio Giving low doses of a particular targeted agent with a cancer-killing virus might improve the effectiveness of the virus as a treatment for cancer, according to a study led by researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

Viruses that are designed to kill cancer cells oncolytic viruses have shown promise in clinical trials for the treatment of brain cancer and other solid tumors. This cell and animal study suggests that combining low doses of the drug bortezomib with a particular oncolytic virus might significantly improve the ability of the virus to kill cancer cells during oncolytic virus therapy.

The research is published in the journal Clinical Cancer Research.

"These findings pave the way for a treatment strategy for cancer that combines low doses of bortezomib with an oncolytic virus to maximize the efficacy of the virus with little added toxicity," says principal investigator Balveen Kaur, PhD, professor and vice chair of research, Department of Neurological Surgery and Radiation Oncology, and a member of the OSUCCC James Translational Therapeutics Program.

"Because bortezomib is already approved by the Food and Drug Administration, a clinical trial could be done relatively quickly to test the effectiveness of the drug-virus combination," Kaur says.

Bortezomib inhibits the activity of proteasomes, structures in cells that break down and recycle proteins. Kaur notes that blocking these "cellular recycling plants" activates a cellular stress response and increases the expression of heat shock proteins. This reaction, which can lead to bortezomib resistance, makes the cells more sensitive to oncolytic virus therapy with little additional toxicity.

For this study, Kaur and her colleagues used a herpes simplex virus-type 1 oncolytic virus. Key technical findings include:
'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. New research could provide key to overcoming resistance to HER2 targeted cancer treatments
2. New Penn-designed gel allows for targeted therapy after heart attack
3. Cancer therapy may be too targeted
4. Researchers develop antibody-targeted treatment for recurrent small-cell lung cancer
5. Scientists uncover image of muscular dystrophy defect & design targeted drug candidates
6. Targeted synthesis of natural products with light
7. Targeted treatment can significantly reduce relapse in children with AML leukemia
8. Fruit pest targeted by genomic research
9. Researchers use nanoscale patches to sensitize targeted cell receptors
10. Targeted culling of deer controls disease with little effect on hunting
11. With early, obvious benefit of a targeted cancer drug, should expensive clinical testing continue?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... nucleotidethe basic building block of DNAcould initiate fragile X syndrome, the ... The Journal of Cell Biology . ... gene on the X chromosome called fragile X mental retardation ... 360 men carry a so-called premutation, in which a series of ... is slightly longer than normal. These repeats are prone to even ...
(Date:9/1/2014)... As nocturnal animals, bats are perfectly adapted to a life ... between the reflected echoes to measure distance to obstacles or ... different echo delays. A study carried out by researchers at ... that this map dynamically adapts to external factors. , ... bat flies in too close to an object, the number ...
(Date:8/31/2014)... Scientists at the University of Warwick have discovered that ... , The substance, methylglyoxal - MG, was found ... of bad cholesterol from the body. , Low ... to heart disease, with increased levels of MG being ... kidney problems. , Supported by funding from the ...
Breaking Biology News(10 mins):A nucleotide change could initiate fragile X syndrome 2Zooming in for a safe flight 2Sugar substance 'kills' good HDL cholesterol, new research finds 2
... carried through the atmosphere before settling on the ocean ... new research from the University of Michigan and the ... Earth Science and Technology (SOEST) combines biogeochemistry and direct ... cycle is colliding with ocean fishand the human seafood ...
... members from The University of Texas at Arlington are ... of Texas System Board of Regents for excellence in ... $25,000 cash award and recognize faculty members at UT ... innovation at the undergraduate level. The professors were recognized ...
... Center Researcher Song-Yi Park, PhD, along with her colleagues, ... vegetables may lower the risk of invasive bladder cancer ... part of the Multiethnic Cohort (MEC) Study, established in ... factors, and cancer risk. Park and her fellow researcher,s ...
Cached Biology News:Ocean fish acquire more mercury at depth 2Ocean fish acquire more mercury at depth 3Ocean fish acquire more mercury at depth 49 UT Arlington educators honored for teaching excellence 2
(Date:8/29/2014)... PA (PRWEB) August 29, 2014 Pittcon ... Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have ... on September 5, 2014. JASIS , Asia’s largest ... 3-5, 2014, in Makuhari Messe, Japan. , The ... Tools for Bioanalysis from Single Molecules to Single Cells” ...
(Date:8/29/2014)... 2014 Local veterinarian, Dr. Keith Clement, ... seeking candidates to participate in an investigational study of ... ultimate goal of this study is to determine if ... or two arthritically affected joints can help reduce pain ... for the current investigational study must be older than ...
(Date:8/29/2014)... Due to a misstatement posted by the ... Stem Cell Technology Center, LLC ( ASCTC ) was reported ... research that might benefit ALS patients. Because of ASCTC's ... cell technologies and therapeutic applications, FRC listed ASCTC as one ... donors who wish not to support research that requires the ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
Breaking Biology Technology:Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... on November 2nd and New York on November ... Inc. (Nasdaq:,FVRL), a biopharmaceutical company developing patient-specific, active,immunotherapies ... the,Company will present at three upcoming investor conferences: ... Ghalie, M.D., Chief Medical Officer, will present at ...
... (Nasdaq:,SIAL), a life science company dedicated to providing ... and Oxford,BioMedica (LSE: OXB), a leading gene therapy ... confirming the strength and validity of,intellectual property owned ... field to Sigma-Aldrich. The ruling was part of ...
... to "de-cloak" cancers -, TORONTO, Oct. 25 ... company discovering and developing the next wave of,antibody ... from its Trop-2 and CD59 antibody programs. ARIUS ... at the AACR press,conference today at 9:30 a.m. ...
Cached Biology Technology:Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference 2Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 2Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 3Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 2Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 3
IC50: 3 ng/ml · Limit of detection: 0.9 ng/ml...
Request Info...
Request Info...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer Pre-designed siRNAs, which ...
Biology Products: